drugset / Trial / NCT06592495

Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315

NCT06592495 ↗

Phase 1 Not yet recruiting 52 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1589 and DWC202315 in healty adult volunteers.

Timeline

Start
2024-10
Primary completion
2025-01
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DWC202315 Unknown — Oral
Subject DWJ1589 Unknown — Oral

Indications

No indication recorded.